FairValu
DANAHER CORP /DE/

DANAHER CORP /DE/

DHRNYSE

Diagnostics & Research • Healthcare

Current Price
$216.070.00%
Market Cap
$151.89B
Shares Outstanding: 702.99M
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for DHR

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for DHR

Factor Scorecard

Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.

23/31 signals active· low confidence at 74% coverage
Overall Factor Score
5440-54 band
Growth
5240-54 band
Quality
7070-84 band
Valuation
290-39 band
Financial Health
6355-69 band

Latest results at a glance

Insights from the latest company results and reports

  • Quarterly Earnings Exceed Consensus

    Reported EPS of $1.94 per share for the quarter ended 2026-06-30 exceeded the same-quarter consensus estimate of $1.84 per share.

  • Revenue Growth Accelerates

    Revenue for the quarter ended 2026-06-26 was $6.27bn, up 5.54% from $5.94bn for the quarter ended 2025-06-27.

  • Net Income Rises Sharply

    Net income for the quarter ended 2026-06-26 was $870.0m, up 56.76% from $555.0m for the quarter ended 2025-06-27.

  • Gross Margin Narrows

    Gross margin for the quarter ended 2026-06-26 was 57.64%, narrower than the 59.35% recorded for the quarter ended 2025-06-27.

  • Bioprocessing Unit Misses Expectations

    [2026-08-14] A financial news outlet reported that Danaher's bioprocessing unit missed expectations in Q2 2026, signaling continued softness in broader biopharma demand.

AI-generated · updated 28 Aug 2026

Price Chart

NYSE:DHR via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
4.6%
Weak
Revenue CAGR 3Y
-
Forward Revenue Growth
7.2%
Moderate
Revenue Acceleration
-9.2%
Slowing

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
5.70
Profitable
EPS Growth
17.3%
Strong
EPS CAGR 3Y
-
EPS Surprise
5.3%
Beat
Forward EPS
8.51
Profitable
Fwd Revenue Growth
7.2%
Forward EPS Growth
9.3%
Moderate

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
58.5%
High
Operating Margin
20.4%
High
Net Margin
15.9%
High
ROE
7.6%
Poor
ROIC
5.4%
Average

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$5.47B
Positive
FCF Growth
12.4%
Moderate
FCF Margin
-
Cash Conversion
1.66x
Excellent

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
25.39x
High
EV / EBITDASupporting
30.25x
High
EV / FCFSupporting
32.65x
High
Trailing P/ESupporting
37.93x
High

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
1.65x
Healthy
Quick Ratio
0.49x
Risky
Debt / Equity
0.51x
Moderate
Interest Coverage
-

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Dividend Yield
0.6%
Low/None
Payout Ratio
24.1%
Sustainable
Buyback Yield
1.9%
Positive
Net Insider Buys
-4
Selling

Peer Comparison

TickerPrice
DHRDANAHER CORP /DE/
$216.07
Company Profile

About the Company

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Next Earnings Date

Oct 20, 2026

Loading latest news...